8-K: Entera Bio Secures Key FDA Nod for Oral Osteoporosis Drug

Entera Bio announced Q2 2025 financial results and a pivotal FDA agreement on the Phase 3 design for its oral osteoporosis treatment, EB613, confirming Bone Mineral Density as the primary endpoint.

Summary

• FDA provided pivotal agreement on Bone Mineral Density (BMD) as the primary endpoint for EB613's Phase 3 study, clearing a streamlined pathway for the first oral anabolic osteoporosis treatment.
• Regulatory burden for EB613 was significantly reduced as the FDA waived additional safety studies, including dedicated oral carcinogenicity and comprehensive nonclinical developmental and reproductive toxicity (DART) studies.
• Cash and cash equivalents totaled $18.9 million as of June 30, 2025, which includes $8.0 million in restricted cash designated to fund the OPKO collaboration, providing a cash runway through mid-Q3 2026.
• Net loss for the three months ended June 30, 2025, was $2.7 million, or $0.06 per ordinary share, compared to a net loss of $2.1 million, or $0.06 per ordinary share, for the same period in 2024.
• Research and development expenses increased by $0.4 million to $1.5 million for Q2 2025, primarily due to regulatory activities and Phase 3 planning for EB613.
• Promising preclinical pharmacokinetic data was presented for the oral GLP-1/glucagon dual agonist program (OPK-88006) in collaboration with OPKO Health, with a Phase 1 study being planned and IND filing expected in H1 2026.
• A next-generation EB613, developed with a new generation of Entera's N-TAB platform, is expected to enter a Phase 1 Safety and PK Study in November 2025.

Sentiment

Score: 8

Explanation: The significant FDA agreement on the Phase 3 design for EB613, including the primary endpoint and waiver of additional safety studies, represents a major de-risking event and a pivotal milestone for the company's lead candidate. This positive regulatory progress, combined with a strong cash runway through mid-Q3 2026 and continued pipeline advancements, outweighs the increased net loss and R&D expenses, which are expected for a clinical-stage company progressing its programs.

Positives

• FDA provided pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint, clearing a streamlined pathway for the first oral anabolic osteoporosis treatment.
• FDA waived additional safety studies (oral carcinogenicity and comprehensive nonclinical DART studies) for EB613, significantly reducing regulatory burden.
• Strong cash position of $18.9 million as of June 30, 2025, including $8.0 million in dedicated OPKO collaboration funding, provides a cash runway through mid-Q3 2026.
• Promising preclinical pharmacokinetic data for the oral GLP-1/glucagon dual agonist program (OPK-88006) with OPKO, showing plasma levels consistent with high subcutaneous doses of Wegovy.
• Next-generation EB613 is advancing and expected to enter Phase 1 in November 2025.
• EB612 oral PTH directed hypoparathyroidism program candidate validation is progressing, with first pre-clinical PK/PD data expected by year-end.
• Strong clinical data for EB613 gained scientific recognition with presentations at the 2025 WCO-IOF-ESCEO Congress and ASBMR 2025.

Negatives

• Net loss increased to $2.7 million for the three months ended June 30, 2025, compared to $2.1 million for the same period in 2024.
• Research and development expenses increased by $0.4 million to $1.5 million for the three months ended June 30, 2025, compared to $1.1 million for the same period in 2024.

Risks

• Changes in the interpretation of clinical data.
• Results of clinical trials may differ from expectations.
• FDA's interpretation and review of clinical trial results and analysis.
• Unexpected changes in ongoing and planned preclinical development and clinical trials.
• Timing of and ability to make regulatory filings and obtain/maintain regulatory approvals for product candidates.
• Potential disruption and delay of manufacturing supply chains.
• Loss of available workforce resources, either by Entera or its collaboration and laboratory partners.
• Impacts to research and development or clinical activities that Entera may be contractually obligated to provide.
• Overall regulatory timelines.
• Ability to establish and maintain development and commercialization collaborations.
• Operation as a development stage company with limited operating history.
• Competitive position with respect to other products on the market or in development for osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions, and other disease categories.
• Ability to continue as a going concern absent access to sources of liquidity.
• Ability to comply with Nasdaq's minimum listing standards and other requirements of being a public company in the United States.
• Intellectual property position and ability to protect intellectual property.

Future Outlook

The company expects to initiate a Phase 3 registrational study for EB613 following FDA alignment on BMD as the primary endpoint. Next-generation EB613 is anticipated to enter a Phase 1 Safety and PK Study in November 2025. For the OPKO collaboration, a Phase 1 study for the oral GLP-1/glucagon candidate (OPK-88006) is being planned, with an IND filing expected in H1 2026. Additionally, first pre-clinical PK/PD data for the EB612 oral PTH directed hypoparathyroidism program is expected by the end of the year.

Management Comments

• "Last week's FDA agreement on using BMD as the primary endpoint for EB613's Phase 3 program represents a pivotal milestone in our journey to bring the first oral anabolic osteoporosis tablet treatment to market."
• "This unprecedented regulatory alignment validates both the strength of our clinical data and our strategic vision that began taking shape in July 2022."
• "The concurrence opens the door to addressing a massive unmet need with less than 25% of the world's 200 million osteoporotic women having access to safe, effective, and affordable treatment options, and no new therapies approved in this space since 2019."
• "Beyond EB613, throughout Q2, we continued building momentum across our entire pipeline, including presenting promising pharmacokinetic data for our oral GLP-1/glucagon dual agonist program with OPKO."
• "With our strengthened cash position of $18.9 million, including dedicated OPKO collaboration funding, we are well-positioned to execute on multiple value-creating milestones across 2025 and beyond."

Industry Context

The announcement highlights a significant unmet need in osteoporosis treatment, noting that less than 25% of the world's 200 million osteoporotic women have access to safe, effective, and affordable treatment options, and no new therapies have been approved in this space since 2019. The company's oral GLP-1/glucagon dual agonist program is positioned against existing obesity treatments, with preclinical data showing plasma levels consistent with high subcutaneous doses of Wegovy (semaglutide), a standard of care.

Comparison to Industry Standards

• The EB613 Phase 3 study design relies on FDA's previous findings of effectiveness and safety for the Reference Listed Drug Forteo, where the correlation between BMD and fracture has been well-established.
• Pharmacokinetic data from the mini-pig study of oral OPK-88006 (dual GLP-1/glucagon receptor agonist) showed plasma levels consistent with those reported in humans for the highest subcutaneous dose of Wegovy (semaglutide) weekly injection, a standard of care for the treatment of obesity.

Stakeholder Impact

• Shareholders: Potential for increased share value due to significant de-risking of the lead drug candidate (EB613) and progress across the pipeline. Increased net loss and R&D expenses reflect ongoing investment in development.
• Patients (Osteoporosis): Potential for a new, convenient oral anabolic treatment option, addressing a significant unmet medical need.
• Patients (Obesity, Hypoparathyroidism, Short Bowel Syndrome): Potential for novel oral peptide therapies in the future.
• Employees: Continued employment and focus on advancing clinical programs.
• OPKO Health (Collaborator): Continued collaboration and progress on joint programs.

Next Steps

• Initiate a Phase 3 registrational study for EB613.
• Next-generation EB613 to enter a Phase 1 Safety and PK Study in November 2025.
• Plan a Phase 1 study for the oral GLP-1/glucagon candidate (OPK-88006).
• File an IND for OPK-88006 in H1 2026.
• Expect first pre-clinical PK/PD data from undisclosed collaborative research for the hypoparathyroidism program by end of year.

Key Dates

Recommendation

The FDA's pivotal agreement on the Phase 3 design for EB613, including the primary endpoint and waiver of additional safety studies, significantly de-risks the lead asset and provides a clear, streamlined path to market for a first-in-class oral anabolic osteoporosis treatment. This regulatory clarity, coupled with a robust cash position extending through mid-Q3 2026 and promising advancements across a diversified pipeline (obesity, hypoparathyroidism), positions Entera Bio for substantial value creation. While the net loss increased, this is typical for a clinical-stage biotech progressing its programs. The potential market for an oral osteoporosis treatment is massive, and the company's progress on this front, along with other pipeline assets, makes it a compelling investment opportunity.

Keywords

Osteoporosis, Oral peptide, EB613, FDA approval, Clinical trials, Biotechnology, Pharmaceuticals, Drug development, GLP-1, Hypoparathyroidism, Entera Bio, N-Tab platform, Bone Mineral Density, OPKO Health